



Akebia Therapeutics to Report First Quarter 2020 Financial Results and Discuss Recent Business Highlights

April 28, 2020

CAMBRIDGE, Mass., April 28, 2020 /PRNewswire/ -- [Akebia Therapeutics](#), Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2020, on Tuesday, May 5, 2020 before the opening of the financial markets.

Akebia will host a conference call at 8:30 a.m. Eastern Time on Tuesday, May 5th, to discuss its first quarter financial results and recent business highlights. To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 8464788. The call will also be webcast LIVE and can be accessed via the Investors section of the Company's website at <http://ir.akebia.com>.

A replay of the conference call will be available two hours after the completion of the call through May 11, 2020. To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number 8464788. An online archive of the conference call can be accessed via the Investors section of the Company's website at <http://ir.akebia.com>.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Investor Contact
Kristen K. Sheppard, Esq
ir@akebia.com

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/akebia-therapeutics-to-report-first-quarter-2020-financial-results-and-discuss-recent-business-highlights-301048115.html>

SOURCE Akebia Therapeutics